Keytruda to be ‘top drug’ by 2023
The current best selling drug is AbbVie and Eisai’s anti-inflammatory therapy, Himura.
Read More
Tag: prediction
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
